Literature DB >> 9700061

Inhibitory NANC neurotransmission in choledocho-duodenal junction of rabbits--a possible role of PACAP.

A Imoto1, R Inoue, M Tanaka, Y Ito.   

Abstract

The pharmacological properties of non-adrenergic non-cholinergic (NANC) inhibitory neurotransmission were investigated in the rabbit choledocho-duodenal junction (CDJ), using the microelectrode and tension recording methods. L-NAME (10(-4) M) and apamin (5 X 10 (-6) M) suppressed NANC relaxation evoked by electrical field stimulation (EFS) in the presence of atropine and guanethidine (each 10(-6) M) to a similar extent (to about 40% of the initial control). However, combined application of L-NAME (10(-4) M) and apamin (5 X 10(-6) M) did not abolish it. EFS also evoked biphasic inhibitory junction potentials (IJPs) consisting of initial fast and slow sustained components in the presence of atropine and guanethidine (each 10(-6) M). Apamin (5 X 10(-8)-5 X 10(-6) M) dose-dependently suppressed the initial fast component by about 70%. In contrast, L-NAME (10(-4) M) did not affect either the amplitude of IJP or the resting membrane potential. PACAP-38 (> 10(-8) M) dose-dependently hyperpolarized the smooth muscle membrane of rabbit CDJ followed by a slow repolarization to the original level. After pretreatment with apamin (5 X 10(-7) M), PACAP-38 (10(-6) M) failed to evoke membrane hyperpolarization. During repolarization in the continued presence of PACAP-38, the amplitude of initial fast component of IJP was reduced to about 40-60% of control value, while that of the slow one was unaffected. A similar suppression of initial fast component of IJP (about 40% of the control value) also occurred after application of PACAP (6-38), a PACAP antagonist, or prolonged treatment with monoclonal antibodies to PACAP-27 or PACAP-38. Furthermore, the substantial part of residual fast IJP in the presence of PACAP (6-38) was suppressed by desensitization to alpha,beta-methylene ATP (10(-3) M). These results indicate that in rabbit CDJ NANC relaxation consists mainly of apamin- and L-NAME-sensitive components, which occur in a membrane potential dependent (through membrane hyperpolarization) and independent fashion, respectively. It has further been suggested that PACAP, together with a smaller contribution of ATP, may be involved as the principal apamin-sensitive transmitter in NANC relaxation of this muscle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700061     DOI: 10.1016/s0165-1838(98)00051-4

Source DB:  PubMed          Journal:  J Auton Nerv Syst        ISSN: 0165-1838


  5 in total

1.  Exogenous adenosine triphosphate and adenosine stimulate proximal sphincter of oddi motility via neural mechanisms in the anesthetized Australian possum.

Authors:  C M Woods; J Toouli; G T P Saccone
Journal:  Dig Dis Sci       Date:  2006-07-11       Impact factor: 3.199

2.  PACAP Modulates Acetylcholine-Elicited Contractions at Nicotinic Neuromuscular Contacts of the Land Snail.

Authors:  Nóra Krajcs; László Hernádi; Zsolt Pirger; Dóra Reglődi; Gábor Tóth; Tibor Kiss
Journal:  J Mol Neurosci       Date:  2015-07-03       Impact factor: 3.444

3.  Cyclic GMP-mediated activation of a glibenclamide-sensitive mechanism in the rabbit sphincter of Oddi.

Authors:  Reka Sari; Barna Peitl; Peter Kovacs; Janos Lonovics; Attila Palvolgyi; Peter Hegyi; Istvan Nagy; Jozsef Nemeth; Zoltan Szilvassy; Robert Porszasz
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

4.  Functional evidence that ATP or a related purine is an inhibitory NANC neurotransmitter in the mouse jejunum: study on the identity of P2X and P2Y purinoceptors involved.

Authors:  Joris G De Man; Benedicte Y De Winter; Tom C Seerden; Heiko U De Schepper; Arnold G Herman; Paul A Pelckmans
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 5.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.